Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q8WXS8
UPID:
ATS14_HUMAN
Alternative names:
-
Alternative UPACC:
Q8WXS8; Q5T4G0; Q5T4G1; Q8TE55; Q8TEY8
Background:
A disintegrin and metalloproteinase with thrombospondin motifs 14 (ADAMTS14) plays a crucial role in the processing of aminoprocollagen type I, independent of ADAMTS2. It is synthesized as a latent enzyme, requiring activation to exhibit aminoprocollagen peptidase activity. Additionally, ADAMTS14 cleaves lysyl oxidase LOX, producing a shorter form of LOX, essential for cross-linking collagen and elastin in the extracellular matrix.
Therapeutic significance:
Understanding the role of A disintegrin and metalloproteinase with thrombospondin motifs 14 could open doors to potential therapeutic strategies, particularly in diseases related to extracellular matrix disorders.